Rebecca Callingham has a diverse work experience in the field of genomics and scientific research. Rebecca currently works at WhiteLab Genomics, where they hold the position of Scientific Project Manager. Prior to this role, they worked as an Application Scientist at the same company, contributing to the development of genomic therapies through the use of AI and computational biology. Before joining WhiteLab Genomics, Rebecca worked as a Funding Adviser at Wellcome Trust, providing guidance and support in funding decisions. Rebecca also gained research experience as a Research Scientist at Imperial College London, where they worked on various scientific projects.
Rebecca Callingham's education history began in 2012 when they enrolled at The Manchester Metropolitan University, where they pursued a Bachelor of Science (BSc) degree in Human Biology. Rebecca completed their undergraduate studies in 2015.
Following their bachelor's degree, Rebecca attended Imperial College London from 2015 to 2016 and obtained a Master of Science (MSc) degree in Genes, Drugs, and Stem Cells.
Continuing their academic journey, Rebecca pursued a Doctor of Philosophy (PhD) at Imperial College London from 2016 to 2020. The field of study for their doctorate degree is unspecified.
In 2021, Rebecca attended SheCodes for a period of one year, specializing in Computer Software Engineering. However, it is important to note that no degree was specified for this program.
Based on the available information, Rebecca Callingham completed their undergraduate studies in Human Biology, followed by a master's degree in Genes, Drugs, and Stem Cells. Rebecca then pursued a doctorate degree at Imperial College London before exploring computer software engineering through an unspecified program at SheCodes.
This person is not in any offices
WhiteLab Genomics
WhiteLab Genomics develops a proprietary platform that leverages graph knowledge technology and machine learning to help companies discover and design new genomic therapies. WhiteLab Genomics enables genomic medicine scientists to obtain precise and comprehensive answers to key scientific and technological questions such as optimizing payload andvector design, assessing genotoxicity, and identifying optimal experimental protocols for in vivo and in vitro strategies. Whitelab Genomics guides its clients through the in-silico development phases, allowing them to quickly develop target vectors and payloads while saving valuable time needed to provide patients with access to new genomic therapies.